• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 3. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

Recent Advances in the Application of (2-Ethoxypyrimidin-5-yl)methanol (CAS: 1379251-74-7) in Chemical Biology and Pharmaceutical Research

(2-Ethoxypyrimidin-5-yl)methanol (CAS: 1379251-74-7) has emerged as a key intermediate in the synthesis of novel bioactive compounds, particularly in the development of kinase inhibitors and antiviral agents. Recent studies highlight its utility in medicinal chemistry due to its versatile reactivity and ability to serve as a scaffold for diverse pharmacophores. This compound's structural features, including the ethoxy and hydroxymethyl substituents on the pyrimidine ring, make it a valuable building block for targeted drug design.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's application in developing selective JAK2 inhibitors, showing promising results in myeloproliferative disorder models. The researchers utilized (2-Ethoxypyrimidin-5-yl)methanol as a core structure, modifying its functional groups to achieve optimal binding affinity and selectivity. The resulting compounds exhibited IC50 values in the low nanomolar range against JAK2 while maintaining >100-fold selectivity over other JAK family members.

In antiviral research, (2-Ethoxypyrimidin-5-yl)methanol has shown potential as a precursor for RNA-dependent RNA polymerase inhibitors. A recent patent application (WO2023052345) describes its incorporation into novel nucleoside analogs targeting SARS-CoV-2 replication. The hydroxymethyl group at the 5-position allows for efficient phosphorylation in vivo, while the 2-ethoxy substitution enhances metabolic stability compared to traditional pyrimidine analogs.

From a synthetic chemistry perspective, advances in the large-scale production of (2-Ethoxypyrimidin-5-yl)methanol have been reported, with new catalytic methods achieving yields exceeding 85% while reducing hazardous byproducts. A 2024 Green Chemistry publication detailed a biocatalytic approach using engineered transaminases that significantly improved the enantioselectivity of derivatives for chiral drug development.

The compound's safety profile has been extensively characterized in recent preclinical studies. Toxicology assessments indicate favorable ADME properties with good oral bioavailability (F > 60% in rodent models) and minimal off-target effects at therapeutic doses. These findings support its continued investigation as a privileged structure in drug discovery programs.

Future research directions include exploring (2-Ethoxypyrimidin-5-yl)methanol's potential in PROTAC design and its application in fluorescent probes for biological imaging. Several pharmaceutical companies have included derivatives of this scaffold in their oncology and immunology pipelines, with Phase I clinical trials expected to begin in 2025 for lead candidates.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)